Detect vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Detect pioneered the FDA-authorized rapid at-home molecular COVID-19 test and is now developing a second-gen molecular diagnostics platform targeting STIs and respiratory infections with 15-minute results.
About
Detect Inc. is a molecular diagnostics company that commercialized one of the first FDA-authorized rapid at-home molecular COVID-19 tests, bringing lab-quality PCR-equivalent results to consumers at home for the first time during the 2021-22 Omicron surge. The company''s proprietary molecular testing platform integrates a reader device and single-use cartridge that performs nucleic acid amplification testing (NAAT) — the gold standard for infectious disease diagnosis — outside of a clinical laboratory setting.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.